Genetic and clinical outcome characteristics of NPM1⁻MN, NPM1⁺MN, and NPM1⁺AML. (A) Heatmap of commonly evaluated genes, cytogenetic findings, and total mutational counts across all cases of NPM1⁻ MN (n = 95), NPM1⁺ MN (n = 45), and NPM1⁺ AML (n = 119). Each column represents an individual patient. All comutations (filled squares = mutation identified) and cytogenetic findings (filled squares = identified deviation from 46,XX or 46,XY) in binary format. Total mutation count per case stratified at greater than (filled square) or less than or equal to 2, by cohort as follows: NPM1⁻ MN (46/95), NPM1⁺ MN (21/45), and NPM1⁺ AML (101/119). *Statistically significant differences in proportions between flanking groups (P < .05, Fisher’s exact test). (B) NPM1⁺ MN (n = 45) exhibit shorter median OS (20 months) than NPM1- MN (36.6 months, n = 95), and NPM1⁺ AML (42.4 months, n = 119).